Clinically, elevated circulating SAA levels have been correlated with poor prognosis in various cancers, including lung and pancreatic cancer, reinforcing its potential role as a prognostic biomarker for immunotherapy resistance (15, 32, 39–41). This evidence concerns the gene SAA1 and pancreatic neoplasm.